Sign in Subscribe

Healthcare Stocks

19
Nov
Stack of hundred dollar bills on dark background with ABBV ticker symbol in white text above

AbbVie: Boring Business, Beautiful Cash Flow

AbbVie survived the Humira patent cliff everyone feared. Now at single-digit P/E with $22B in free cash flow and a 3% yield, you're paying for pharma discipline while others chase biotech moonshots. Sometimes boring wins.
3 min read
04
Oct
JNJ thumbnail with bold text ‘Dividend King or Lawsuit Trap?’ over a gavel and pill bottle.

$JNJ: Dividend King or Lawsuit Trap?

JNJ isn’t broken. But at $188, you’re paying growth multiples for a dividend stock with unlimited liability. That’s not prudent — that’s hopeful.
2 min read
Questions? Email Phaetrix